Merck is a high-quality pharma franchise with strong cash flow, but the stock is balancing new product growth against looming Keytruda exclusivity risk. The shares look fairly valued at current levels, supporting a Hold.
Merck & Company Inc (MRK) is a high-quality but transition-sensitive pharmaceutical company. The investment case rests on three facts: 2025 revenue reached approximately $65.0B, 2025 free cash flow was $12.4B, and the company is building replacement growth through Winrevair, Capvaxive, Keytruda Qlex, Ohtuvayre, LIPFENDRA, and a broad oncology pipeline. The central risk is concentration. Keytruda generated $31.7B in 2025, while U.S. biosimilar competition could begin in December 2028.
The latest quarter showed both sides of the story. Q2 2026 revenue rose 5% to $16.6B, with Keytruda family sales up 4% to $8.4B, Winrevair sales up 75% to $588M, and Welireg sales up 67% to $271M. At the same time, the Terns Pharmaceuticals acquisition created a $5.7B charge, pushed non-GAAP EPS to a $0.13 loss, and lowered full-year 2026 non-GAAP EPS guidance to $2.66-$2.76.
MRK suits a moderate-risk investor seeking a large, cash-generative healthcare franchise with a medium-term horizon, but the current price does not offer a wide margin of safety. At a cited price of $136.09, a forward P/E of 54.1x and PEG ratio of 14.3x leave the shares dependent on successful pipeline execution. The recommendation is Hold, with an estimated fair value of $140.
Merck is a global healthcare company headquartered in Rahway, New Jersey, with approximately 73,000 employees. Founded in 1891, it operates through Pharmaceutical and Animal Health segments and sells prescription medicines, vaccines, veterinary products, and animal health services.
The business model combines patent-protected products with a global commercial network serving wholesalers, retailers, hospitals, government agencies, physicians, and distributors. Approximately 44% of 2025 sales came from outside the U.S., giving MRK meaningful geographic reach but also exposing revenue to currency movements, local reimbursement systems, and regional demand changes.
Merck's stated One Pipeline strategy combines internal research with licensing, partnerships, and acquisitions. Management said the company has spent more than $65B on business development since 2021 and identified greater than $70B of commercial opportunity from more than 20 new products. That strategy has expanded the opportunity set, although the $5.7B Terns charge shows that portfolio renewal can be expensive before acquired assets produce revenue.
Pharmaceuticals is the economic engine. In 2025, the segment generated $58.1B, or 89.4% of total revenue. Animal Health contributed $6.4B, or 9.8%, while other segments contributed $515M. This mix gives MRK scale in human medicines while Animal Health adds a steadier, separate source of demand.
Q2 2026 Human Health sales were $14.8B, up 5%, while Animal Health sales were $1.8B, up 8% nominally and 5% excluding foreign exchange. Pharmaceutical growth came from oncology and new launches. Animal Health livestock sales rose 6%, and companion animal sales rose 5% because of new product launches.
Within Pharmaceuticals, oncology remains dominant. The Keytruda family produced $8.4B in Q2 sales, Gardasil produced $1.2B, Winrevair produced $588M, Ohtuvayre produced $204M, Capvaxive produced $184M, and Welireg produced $271M. The breadth is improving, but Keytruda still sets the financial rhythm for the company.
Animal Health is strategically important because its products span livestock vaccines, livestock intelligence, companion animal medicines, and veterinary services. Management has described a goal of doubling the segment from its 2024 base by the mid-2030s. Q2 sales growth of 5% excluding foreign exchange supports that ambition, although the segment remains too small to offset a rapid Keytruda decline by itself.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Keytruda is the core asset. Keytruda and Keytruda Qlex generated approximately $31.7B in 2025 sales, up 7%, and the family generated $8.4B in Q2 2026, up 4%. Growth came from earlier-stage cancers, metastatic indications, breast and cervical cancers, and use with Padcev in locally advanced or metastatic urothelial cancer.
Keytruda Qlex generated $463M in Q2 2026 after its U.S. launch in September 2025. The permanent J-code became effective in April 2026, and management reported increasing physician and patient adoption. The subcutaneous formulation improves administration convenience and can help defend the franchise, but it does not remove the underlying exposure to eventual loss of exclusivity.
Merck's 2025 filing identified potential U.S. biosimilar competition for Keytruda beginning in December 2028, with European exclusivity expected to end in 2031. Management also said U.S. Keytruda growth should moderate as penetration approaches peak in several major indications. This creates a clock: new products must scale before the largest revenue contributor faces direct erosion.
Gardasil is the second major concentration point. The franchise generated approximately $5.2B in 2025 sales, while Q2 2026 sales were $1.2B, up 3%. International sales rose 6%, but U.S. demand was roughly flat. Merck paused Gardasil shipments to China in February 2025 because of elevated inventory at its commercialization partner, and China sales did not materially improve in 2026.
Winrevair is the most visible newer growth engine. Q2 sales rose 75% to $588M, and first-half 2026 sales reached $1.1B. Continued prescription growth in pulmonary arterial hypertension, including more than 1,800 newly prescribed U.S. patients in Q2, gives MRK a credible path toward a new blockbuster franchise.
MRK's strongest competitive advantage is the combination of scientific scale, regulatory experience, and commercial reach. Keytruda has expanded into 13 earlier-stage indications, while the company continues to develop combinations and new formulations around the asset. That installed base gives MRK a large clinical and commercial platform that smaller biotechnology companies cannot easily replicate.
The pipeline is broad across oncology, cardiometabolic disease, HIV, immunology, respiratory disease, and infectious disease. LIPFENDRA became the first approved oral PCSK9 inhibitor, and the CORALreef Lipids trial showed LDL reductions of up to 60% when added to a statin. Tulisokibart produced positive Phase III induction results in ulcerative colitis and positive results in hidradenitis suppurativa, although its systemic sclerosis-associated interstitial lung disease study did not meet its primary endpoint.
In oncology, sac-TMT produced statistically significant and clinically meaningful improvements in overall survival and progression-free survival versus chemotherapy in certain patients with advanced or recurrent endometrial cancer. The TroFuse program includes 17 Phase III studies. Management also described sac-TMT as a potential cornerstone antibody-drug conjugate and said the company is reconsidering first-line lung cancer combinations after positive partner data.
The HIV pipeline adds another layer of optionality. IDVYNSO launched as a once-daily oral two-drug regimen for certain virologically suppressed adults. The islatravir and lenacapavir combination produced Phase III results supporting a potential once-weekly oral treatment, while alimatravir is in Phase III studies as a once-monthly oral pre-exposure prophylaxis candidate. These programs are valuable because they diversify MRK beyond oncology, although clinical success does not automatically translate into commercial scale.
MRK operates a high-margin pharmaceutical model, but recent figures show meaningful cost pressure. Q2 2026 non-GAAP gross margin was 81.1%, down 1.1 percentage points because of higher inventory reserves. Operating expenses reached $12.6B, including a $5.7B Terns acquisition charge and higher spending to support product launches and pipeline development.
Excluding the Terns charge, operating expenses grew 7% in Q2. Management cited launch investment, early- and late-stage research, and financing costs from recent business development transactions. Multiyear optimization efforts and external funding for sac-TMT development partly offset those expenses.
The Ohtuvayre launch illustrates the operational detail required in specialty pharmaceuticals. Management said second-quarter specialty pharmacy purchases benefited reported sales and that the third quarter would include a reversal of that purchase timing. The company is investing in its U.S. sales force and working with specialty pharmacies to improve the patient experience. That approach can support adoption, but it also makes quarterly revenue timing less smooth.
MRK also maintains financial flexibility for additional transactions. Management cited a strong investment-grade credit rating, a high priority for business development, and approximately $3B of planned 2026 share repurchases. The balance between acquisitions, pipeline investment, dividends, and repurchases will matter because the Terns deal already increased debt and depressed reported earnings.
The global pharmaceutical market was estimated at $1.77T in 2025 and is projected by Mordor Intelligence to reach $2.31T by 2031, a 5.5% CAGR. Oncology is the most relevant market for MRK, with global oncology sales estimated at approximately $288B in 2025. This large market supports sustained demand for differentiated therapies, but it also attracts intense competition and regulatory scrutiny.
Oncology development is moving toward antibody-drug conjugates, cell and gene therapies, radiopharmaceuticals, and multispecific antibodies. These modalities represented approximately 33%-35% of oncology trial starts in 2025. MRK's sac-TMT program fits directly into that shift, while its Keytruda combination strategy helps the company use an established immunotherapy platform alongside newer technologies.
The market also rewards measurable outcomes and penalizes weak differentiation. Health technology assessment and payer scrutiny are increasing, while real-world evidence and value-based pricing are becoming more important in commercialization. MRK's strong clinical results in Keytruda, Winrevair, and selected pipeline programs support access, but price pressure remains a structural feature of the industry.
Biologics and biosimilars are expected to grow faster than conventional drugs, with biologics and biosimilars forecast to expand at an 8.2% CAGR through 2031 in Mordor Intelligence's market view. That creates opportunity for MRK's biologic portfolio and risk for mature products once competing versions enter the market.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
MRK sells into a layered healthcare purchasing system rather than directly to a single customer type. Its channels include wholesalers, retailers, hospitals, physicians, government agencies, distributors, specialty pharmacies, and veterinary providers. The mix changes by product: Keytruda depends heavily on oncology treatment centers and reimbursement systems, while vaccines involve public health agencies, clinics, and government purchasing.
The Q2 2026 results show how customer access affects product performance. Keytruda Qlex adoption increased after the permanent J-code took effect in April. Ohtuvayre sales benefited from specialty pharmacy purchases, and management said improved specialty pharmacy support is part of the plan to accelerate growth in 2027.
International customers are also central to the model. Forty-four percent of 2025 sales came from outside the U.S., Gardasil international sales rose 6% in Q2 2026, and Capvaxive growth was supported by launches in international markets. The same global footprint creates exposure to local pricing controls, government purchasing cycles, currency changes, and the China Gardasil inventory issue.
Bristol Myers Squibb competes with Keytruda through Opdivo, while Roche competes through Tecentriq. AstraZeneca is active in immuno-oncology, lung cancer, and combination regimens. Pfizer and Astellas are relevant in uro-oncology, where Merck's Keytruda and Padcev combination competes in a crowded treatment environment.
Vaccines face a separate competitive set. Pfizer competes with Capvaxive in pneumococcal vaccines, and GSK competes with Gardasil in HPV vaccines and with MRK in respiratory markets. The Gardasil sales decline reported in 2025, driven mainly by lower China demand and Japan timing, demonstrates that a strong franchise can still face regional demand shocks.
Zoetis is the most relevant listed competitor in Animal Health. MRK's advantage is the combination of a large human health platform and a meaningful veterinary business, while Zoetis has greater pure-play focus. MRK's product breadth lowers dependence on a single therapeutic area over time, but the 89.4% Pharmaceutical revenue mix means the company remains primarily exposed to prescription drug competition.
The key competitive advantage is not a lack of rivals. It is MRK's ability to fund large clinical programs, run global trials, secure regulatory approvals, and commercialize products across multiple countries. The risk is that competitors advance faster in antibody-drug conjugates, immunology, or oncology combinations while Keytruda approaches peak penetration.
Drug pricing and reimbursement are the main macro forces affecting MRK. Payers are increasing the use of real-world evidence, value-based pricing, and cost-containment tools. These policies can reduce pricing power unless a medicine shows clear clinical or economic benefits.
Currency also affects reported results. MRK's 2026 revenue guidance includes an estimated 1 percentage point foreign exchange benefit, and Q2 revenue grew 5% nominally versus 4% excluding foreign exchange. That gap shows how currency can alter reported growth without changing underlying demand.
China is a specific geopolitical and commercial risk for Gardasil. MRK paused shipments in February 2025 because of elevated channel inventory, and China sales did not materially improve in 2026. The event shows how government-linked purchasing, local inventory, and regional policy can affect a global product even when the underlying medical need remains.
Regulatory modernization is a potential efficiency tailwind. The FDA is pursuing streamlined nonclinical safety approaches for certain oncology drugs and broader efforts to reduce animal testing. Faster development would benefit a company with MRK's late-stage pipeline, but regulatory approval remains dependent on clinical evidence and product-specific review.
Merck generated $12.4B in free cash flow in 2025, but the $5.7B Terns charge and transition-heavy pipeline spending show why balance sheet flexibility matters.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q2 2026 revenue rose 5% to $16.6B, yet a $5.7B acquisition charge pushed non-GAAP EPS to a $0.13 loss and cut full-year guidance to $2.66-$2.76.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management now expects 2026 non-GAAP EPS of $2.66-$2.76 after the Terns deal, underscoring how pipeline investment is pressuring near-term earnings.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At $136.09, Merck trades at 54.1x forward earnings and a 14.3x PEG, leaving little margin of safety unless new launches keep compounding quickly.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →With a Hold rating and fair value of $140, the shares sit close to the analyst view of intrinsic worth rather than offering a deep discount.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →MRK is a strong pharmaceutical franchise entering a demanding transition period. Its 2025 revenue base, $12.4B of free cash flow, 82.7% institutional ownership, and global commercial platform provide stability. The latest quarter also confirmed tangible momentum in Winrevair, Welireg, Capvaxive, Keytruda Qlex, and new product launches.
The valuation keeps the conclusion measured. A 119.2x trailing P/E, 54.1x forward P/E, rising debt, and the approaching Keytruda exclusivity event make the stock less compelling as a bargain, even though the pipeline offers meaningful upside. MRK earns a Hold recommendation for a moderate-risk, medium-term investor, with $140 as the report's fair value estimate and $115 as the more attractive entry target.
The strategic question is no longer whether Merck can produce growth products. Winrevair, Capvaxive, and the clinical pipeline show that it can. The more demanding test is whether those products can scale fast enough, and profitably enough, to replace a mature Keytruda franchise without requiring another large acquisition. The current evidence supports patience rather than aggressive accumulation.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Merck & Co., Inc. (MRK) climbs after late-stage melanoma vaccine headlines tied to Moderna and Keytruda. The rally reflects renewed pipeline optimism, stronger sentiment, and investor focus on future oncology growth.
Merck’s patent-cliff problem is real, but the market is acting like the runway ends tomorrow when the core franchise is still expanding today. Fresh lung-cancer data, rising Keytruda sales, and a packed oncology catalyst calendar make MRK look stronger than the fear trade suggests.
Merck & Co., Inc. (MRK) rises after positive Phase 3 lung cancer data and a favorable European regulatory opinion for a Keytruda regimen. The move reflects renewed confidence in Merck’s oncology pipeline and its ability to extend growth beyond Keytruda alone.